Genmab AS

Genmab AS EPS

The Earnings per Share (EPS) of Genmab AS (GMAB) as of Nov 22, 2026 is 1.43 USD. In the previous year, Earnings per Share (EPS) was 12.23 USD — a change of -88.28% (lower).

EPS

1.43USD

YoY

-88.28%

Last updated:

Earnings per Share (EPS) of Genmab AS is 2025 1.43 USD. Earnings per Share (EPS) of Genmab AS was 2024 12.23 USD. It decreases by -88.28% lower compared to the previous year.

The Genmab AS EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2023
6.62 USD
Jan 1, 2024
12.23 USD
Jan 1, 2025
1.43 USD
Jan 1, 2026 (e)
1.25 USD
Jan 1, 2027 (e)
1.63 USD
Jan 1, 2028 (e)
2.70 USD
Jan 1, 2029 (e)
3.11 USD
Jan 1, 2030 (e)
3.65 USD
The Genmab AS EPS history
YEAREPSYoY
est3.65USD+17.34%
est3.11USD+15.12%
est2.70USD+66.17%
est1.63USD+30.17%
est1.25USD-12.85%
1.43USD-88.28%
12.23USD+84.83%
6.62USD-19.83%
8.25USD+84.58%
4.47USD-37.91%
7.20USD+118.70%
3.29USD+38.87%
2.37USD+33.70%
1.77USD-7.55%
1.92USD+49.33%
1.28USD+146.40%
0.52USD+147.04%
0.21USD-120.69%
-1.02USD-23.28%
-1.33USD+85.75%
-0.72USD-68.18%
-2.25USD+4.06%
-2.16USD+147.81%
-0.87USD-22.51%
-1.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Earnings per Share (EPS) of Genmab AS is 1.43 USD in 2025.

Earnings per Share (EPS) of Genmab AS changed from 12.23 USD to 1.43 USD, representing a -88.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genmab AS

All Key Metrics — Genmab AS